Market Research Industry Reports

Seattle Genetics Inc (SGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. The companys lead product Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) indicated for the treatment of relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics product pipeline consists of ASG-22ME (enfortumab vedotin) for metastatic urothelial cancer. Its pipeline also comprises various antibody-drug conjugate (ADC) programs and immuno-oncology programs in various clinical stages of development. It uses ADC and sugar-engineered antibody (SEA) technologies for the development of its product portfolio. The company sells its products through pharmaceutical distributors and collaborators. Seattle Genetics is headquartered in Bothell, Washington, the US.

Seattle Genetics Inc (SGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Seattle Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Seattle Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 13
Venture Financing 14
Unum Therapeutics Raises USD65 Million in Series B Financing 14
Partnerships 16
Seattle Genetics Enters into Clinical Agreements for SGN-LIV1A 16
Seattle Genetics Enters into Agreement with Genentech 17
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 18
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 19
Genmab Enters into Research Agreement with Seattle Genetics 20
Seattle Genetics Expands Co-Development Agreement With AbbVie 21
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 22
Licensing Agreements 23
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 23
Seattle Genetics Enters into Licensing Agreement with Pieris Pharma 24
Bayer HealthCare Enters Into Licensing Agreement With Seattle Genetics 25
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 26
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 27
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 28
Equity Offering 29
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 29
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 31
Unum Therapeutics Plans to Raise USD5 Million in Private Placement of Shares 33
Seattle Genetics Completes Private Placement Of Shares For US$9 Million 34
Acquisition 35
Seattle Genetics Acquires Cascadian Therapeutics for USD614 Million in Tender Offer 35
Seattle Genetics Acquires 2.8% Stake in Immunomedics 37
Seattle Genetics Inc - Key Competitors 39
Seattle Genetics Inc - Key Employees 40
Seattle Genetics Inc - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Feb 06, 2018: Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results 42
Oct 26, 2017: Seattle Genetics Reports Third Quarter 2017 Financial Results 45
Jul 27, 2017: Seattle Genetics Reports Second Quarter 2017 Financial Results 47
Apr 27, 2017: Seattle Genetics Reports First Quarter 2017 Financial Results 49
Feb 09, 2017: Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results 51
Product News 53
04/03/2017: Unum Therapeutics to Present New Data on its Antibody-Coupled T Cell Receptor Platform at the Upcoming American Association for Cancer Research 2017 Annual Meeting 53
Mar 30, 2017: Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting 55
01/21/2017: Johnson & Weaver Announces Filing of Class Action Complaint Against Seattle Genetics Encourages all Investors to Contact the Firm for Information 57
Jan 08, 2018: Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference 58
Clinical Trials 59
Dec 07, 2017: Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium 59
Mar 06, 2017: FDA Lifts Clinical Hold on Seattle Genetics Phase 1 Trials of Vadastuximab Talirine 61
Jan 05, 2017: Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List Of Tables

List of Tables
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Seattle Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Seattle Genetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Seattle Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 13
Unum Therapeutics Raises USD65 Million in Series B Financing 14
Seattle Genetics Enters into Clinical Agreements for SGN-LIV1A 16
Seattle Genetics Enters into Agreement with Genentech 17
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 18
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 19
Genmab Enters into Research Agreement with Seattle Genetics 20
Seattle Genetics Expands Co-Development Agreement With AbbVie 21
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 22
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 23
Seattle Genetics Enters into Licensing Agreement with Pieris Pharma 24
Bayer HealthCare Enters Into Licensing Agreement With Seattle Genetics 25
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 26
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 27
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 28
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 29
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 31
Unum Therapeutics Plans to Raise USD5 Million in Private Placement of Shares 33
Seattle Genetics Completes Private Placement Of Shares For US$9 Million 34
Seattle Genetics Acquires Cascadian Therapeutics for USD614 Million in Tender Offer 35
Seattle Genetics Acquires 2.8% Stake in Immunomedics 37
Seattle Genetics Inc, Key Competitors 39
Seattle Genetics Inc, Key Employees 40
Seattle Genetics Inc, Subsidiaries 41

List Of Figures

List of Figures
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Seattle Genetics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Seattle Genetics Inc (SGEN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. The companys lead product Adcetris (brentuximab vedotin) is an

USD 250View Report

Seattle Genetics Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Seattle Genetics Inc Company Profile is a detailed strategic and analytical report on Seattle Genetics Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Seattle Genetics Inc (SGEN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. The companys lead product Adcetris (brentuximab vedotin) is an

USD 250View Report

Signal Genetics Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Signal Genetics Inc Company Profile is a detailed strategic and analytical report on Signal Genetics Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :63
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube